2017 – Hard work and good times
17 January 2018
The twelve months of the year 2017 rushed through like Usain Bolt, faster than ever and celebrating with hands in the air on the way. Or in other words, it was a very nice year for Admescope, being the strongest period in our history, with 20% increase in revenue and tens of new satisfied customers.Read more
The new FDA draft guidance on DDI studies – how does it affect in vitro studies?
1 December 2017
Recently FDA released new draft guidance on drug-drug interaction (DDI) studies. Compared to the previous one issued in 2012, also the structure is revised as there is now two complementary documents. The “In Vitro Metabolism- and Transporter –Mediated Drug-Drug Interaction Studies” focuses on in vitro approaches to evaluate potential interaction risk,Read more
ADME-Tox e-books – why are we doing these?
16 August 2017
Working at a CRO is not only about providing research services, but also about helping and supporting customers in different ways throughout the process. We have the pleasure to work with a wide variety of customers, ranging from small biotech and academic research groups to Big Pharma companies.Read more
HR-MS – when does it make a difference?
6 June 2017
In addition to knowledge and knowhow regarding the early phase ADME studies, also the analytical instrumentation applied plays a big role in their success. The importance of using liquid chromatography coupled to high resolution mass spectrometry (LC/HR-MS) in drug discovery and preclinical phase ADME studies has been emphasized for few years, but when does it really make a difference? To elucidate the topic further, we interviewed an expert in the field, Dr Ari Tolonen.Read more
A day in the lab with two Admescope technicians
3 March 2017
We are both early birds, waking up around 6am. While the other starts the morning by taking the dog for a walk followed by a bike ride to work, the other one drives kids to daycare and then goes for ice swimming. Yep, it is winter time in FinlandRead more
